Related Experiment Video
Updated: Apr 6, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Comorbidity as a driver of adverse outcomes in people with chronic kidney disease
Marcello Tonelli1, Natasha Wiebe2, Bruce Guthrie3
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Insights
Chronic kidney disease (CKD) patients face poor outcomes due to numerous comorbidities. Both concordant and discordant conditions, including mental health issues, independently drive adverse events in CKD.
Area of Science:
- Nephrology
- Epidemiology
- Public Health
Background:
- Chronic kidney disease (CKD) is linked to adverse outcomes, often attributed to comorbidity burden.
- Existing research primarily examines concordant comorbidities (e.g., hypertension, diabetes) in CKD.
- The impact of mental health conditions and discordant comorbidities on CKD outcomes remains less understood.
Purpose of the Study:
- To investigate the association between comorbidity burden, including mental health and discordant conditions, and adverse clinical outcomes in a large CKD population.
- To determine if discordant comorbidities and mental health conditions are independent predictors of adverse outcomes in CKD patients.
Main Methods:
- Retrospective population-based cohort study of 530,771 adults with CKD in Alberta, Canada (2003-2011).
- Utilized validated algorithms on provincial health data to identify 29 chronic comorbidities.
- Comorbidities categorized as concordant, mental health/chronic pain, or discordant; linked to outcomes (mortality, hospitalization, myocardial infarction) over a median 48-month follow-up.
Main Results:
- The median comorbidity count was 1, with 25% having ≥3 and 7% having ≥5 comorbidities.
- Concordant comorbidities significantly increased hospitalization risk.
- Discordant comorbidities and mental health conditions also independently elevated the risk of adverse outcomes.
Conclusions:
- Comorbidity burden significantly impacts CKD outcomes.
- Discordant comorbidities and mental health conditions are crucial, independent contributors to adverse events in CKD.
- Clinical management of CKD should address the full spectrum of comorbidities, not just those directly causing or commonly accompanying CKD.
Abstract:
Chronic kidney disease (CKD) is associated with poor outcomes, perhaps due to a high burden of comorbidity. Most studies of CKD populations focus on concordant comorbidities, which cause CKD (such as hypertension and diabetes) or often accompany CKD (such as heart failure or coronary disease). Less is known about the burden of mental health conditions and discordant conditions (those not concordant but still clinically relevant, like dementia or cancer). Here we did a retrospective population-based cohort study of 530,771 adults with CKD residing in Alberta, Canada between 2003 and 2011. Validated algorithms were applied to data from the provincial health ministry to assess the presence/absence of 29 chronic comorbidities. Linkage between comorbidity burden and adverse clinical outcomes (mortality, hospitalization or myocardial infarction) was examined over median follow-up of 48 months. Comorbidities were classified into three categories: concordant, mental health/chronic pain, and discordant. The median number of comorbidities was 1 (range 0-15) but a substantial proportion of participants had 3 and more, or 5 and more comorbidities (25 and 7%, respectively). Concordant comorbidities were associated with excess risk of hospitalization, but so were discordant comorbidities and mental health conditions. Thus, discordant comorbidities and mental health conditions as well as concordant comorbidities are important independent drivers of the adverse outcomes associated with CKD.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology

